drugset / Trial / NCT00216398

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

NCT00216398

Phase 4 Completed 8 enrolled Ipsen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.

Timeline

Start
2004-06
Primary completion
2006-06-22
Completion
2006-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanreotide Other / unclassified

Indications